Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avantis US Small Cap Value ETF (AVUV) vs Twist Bioscience Corp (TWST) Price & Performance

Avantis US Small Cap Value ETFTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Avantis US Small Cap Value ETF vs Twist Bioscience Corp — how do they compare? Avantis US Small Cap Value ETF trades at $127.8, while Twist Bioscience Corp trades at $124 (market cap $7.72B). Which is the better fit depends on your goals.

AVUVTWST
Sector
Sector/ThematicHealth
52-Week High
$128.74$124.88
52-Week Low
$93.93$24.16
Market Cap
$7.72B
Enterprise Value
$7.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avantis US Small Cap Value ETF

AVUV trades at $126.88, up 0.36% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights strong small-cap value performance and potential benefits from rate outlook shifts. The ETF focuses on U.S. small-cap value stocks, offering diversification from tech-heavy portfolios.

Outlook remains positive due to small-cap momentum and value factor tailwinds, but risks include higher volatility and sensitivity to interest rates. Analyst sentiment is favorable, emphasizing long-term growth potential in tax-advantaged accounts like Roth IRAs.

Twist Bioscience Corp

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Avantis US Small Cap Value ETF

AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.

Read more on AVUV

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST